Review

Porous Nanomaterials Targeting Autophagy in Bone Regeneration

Qing Zhang 1,2,†, Lan Xiao 1,3,4,† and Yin Xiao 1,3,4,*

1 Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Guangzhou 510182, China; zhangqing@gzhmu.edu.cn (Q.Z.); l5.xiao@qut.edu.au (L.X.)
2 Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, 1081 BT Amsterdam, The Netherlands
3 Centre for Biomedical Technologies, School of Mechanical, Medical and Process Engineering, Queensland University of Technology, Brisbane, QLD 4000, Australia
4 The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Queensland University of Technology, Brisbane, QLD 4000, Australia
* Correspondence: yin.xiao@qut.edu.au
† These authors contributed equally to this work.

Abstract: Porous nanomaterials (PNMs) are nanosized materials with specially designed porous structures that have been widely used in the bone tissue engineering field due to the fact of their excellent physical and chemical properties such as high porosity, high specific surface area, and ideal biodegradability. Currently, PNMs are mainly used in the following four aspects: (1) as an excellent cargo to deliver bone regenerative growth factors/drugs; (2) as a fluorescent material to trace cell differentiation and bone formation; (3) as a raw material to synthesize or modify tissue engineering scaffolds; (4) as a bio-active substance to regulate cell behavior. Recent advances in the interaction between nanomaterials and cells have revealed that autophagy, a cellular survival mechanism that regulates intracellular activity by degrading/recycling intracellular metabolites, providing energy/nutrients, clearing protein aggregates, destroying organelles, and destroying intracellular pathogens, is associated with the phagocytosis and clearance of nanomaterials as well as material-induced cell differentiation and stress. Autophagy regulates bone remodeling balance via directly participating in the differentiation of osteoclasts and osteoblasts. Moreover, autophagy can regulate bone regeneration by modulating immune cell response, thereby modulating the osteogenic microenvironment. Therefore, autophagy may serve as an effective target for nanomaterials to facilitate the bone regeneration process. Increasingly, studies have shown that PNMs can modulate autophagy to regulate bone regeneration in recent years. This paper summarizes the current advances on the main application of PNMs in bone regeneration, the critical role of autophagy in bone regeneration, and the mechanism of PNMs regulating bone regeneration by targeting autophagy.

Keywords: nanomaterials; autophagy; osteogenesis; immune microenvironment; bone; regenerative medicine

1. Introduction

Bone is a metabolically active tissue that maintains physiological function and homeostasis through a continuous remodeling process that consists of bone resorption and formation [1]. For large bone defects caused by tumor, trauma, inflammation, or infection, it is necessary to implant materials to promote new bone regeneration and restore bone function. From the view of materials, healthy bone is a complex natural material composed of organic nanomaterials (collagen, nanofibers) and inorganic nanomaterials (nano-hydroxyapatite) with a multi-level structure from the micro-nanometer to the macro-level [2]. This multilayered structure is also linked to responding to stimuli/injury and
activating regeneration [2]. Therefore, nanomaterials have a broad prospect for the development of functional bone regenerative materials. In recent years, nanomaterials have attracted increasing interest in bone regeneration studies, and many reviews have reported on the application of nanomaterials for bone regeneration. For instance, as early as 2009, Webster, T.J., reviewed the prospects for nanomaterials in bone, cartilage, blood vessel, nerve, and bladder tissue engineering [3]. Srinivasan, D.K., elucidated the use of nanoparticles as a drug delivery system to improve bone regeneration [4]. Liu, C., summarized the development of nanomaterials that can promote bone regeneration in a mimicked bone-healing model (e.g., compositional, nanocrystal formation, structural, and growth factor-related mimicking) [2]. Meanwhile, the mechanisms by which nanomaterials regulate cell behavior have been widely investigated [5]. Studies on the interactions between nanomaterials and cells have shown that cell phagocytosis and clearance of nanomaterials, cell function maintenance, cell differentiation, and stress response are strictly regulated by autophagy [6].

Autophagy is the response of cells to stress. It is an evolutionarily conserved process with multiple roles. Primarily, it maintains intracellular homeostasis by degrading and circulating metabolites within cells, providing energy and nutrients, eliminating cytotoxic substances such as damaged proteins and organelles [7]. Interestingly, in the skeletal system, autophagy activated by specific nanomaterials contributes to osteogenic differentiation [7,8]. At the same time, other studies have shown that the toxic effects of nanomaterials may also be associated with autophagy [9], which leads to bone loss [10] and osteolysis [11,12]. During bone remodeling, autophagy plays a vital role in the differentiation of osteoclasts and osteoblasts via the mediating immune regulation [13]. These results suggest that autophagy plays a bi-directionally regulatory role in the process of promoting or inhibiting osteogenesis; therefore, targeting autophagy is of great significance for the design of bone regenerative nanomaterials. Hence, targeting autophagy may be a practical approach for promoting bone regeneration.

PNMs are nanomaterials with a porous structure and high surface ratio, which are widely used in the fields of biomedical engineering [14–18] such as bone regeneration [18–21], drug delivery [22–24], cell trace, and regulation of cell differentiation. Since 2014, it has been reported that mesoporous bioactive glass nanomaterials can promote osteogenic differentiation through activation of autophagy [25]. Targeting autophagy has become a new research focus in the application of PNMs for bone regeneration. In the current review, the main application of PNMs in bone regeneration is summarized. Then, the crucial regulatory role of autophagy in bone regeneration is briefly introduced. The regulatory roles of PNMs, including mesoporous silica nanoparticles (MSNs) [20,26,27], mesoporous hydroxyapatite nanoparticles (HAP) [28–30], alumina nanoparticles (Al₂O₃) [31,32], mesoporous bioactive glass nanoparticles (MBGNs) [33–36], mesoporous ceria (MCeO₂) [37,38], and metallic oxides [39,40] in bone regeneration via targeting autophagy, are reviewed and discussed.

2. PNMs for Bone Regeneration

The type, structure, and morphology of nanomaterials have been continuously improved to achieve better bone regeneration. In particular, PNMs with porous structures have aroused the interest of researchers. Compared with nanomaterials without pores, porous materials have higher porosity and higher specific surface area. The high porosity facilitates the design for an excellent drug delivery carrier, and the high specific surface area makes it easily modifiable with bioactive molecules. The application of PNMs in bone regeneration is mainly focused on the following four aspects (Figure 1).
Figure 1. Schematic diagram of PNM applications in bone regeneration. MSCs: mesenchymal stem cells; CT: computer tomography.

(1) PNMs can be designed as efficient nanocarriers to promote bone regeneration through (controlled) delivery of beneficial factors such as small molecule compounds, genes, and proteins. A variety of microporous (<2 nm), mesoporous (2~50 nm), and macropore nanomaterials (>50 nm) are designed as drug delivery carriers [41]. In particular, due to the high porosity and specific surface area, PNMs are widely used to deliver drugs for bone regeneration such as mesoporous silica nanoparticles [42–44] and mesoporous hydroxyapatite nanoparticles [29,30,45]. The hollow and mesoporous structure of nanomaterials can enhance drug loading efficiency [46]. For example, Hae-Won Kim [36] used hollow porous nanoparticles to deliver small genetic molecules to silence the target gene thereby, in turn, stimulating osteogenic differentiation. In another study, mesoporous silica nanoparticles have been combined with hydroxyapatite to generate a composite coating for implant surface modification, which served as a drug-delivery tool to suppress osteoclastogenesis for improving bone regeneration and osteointegration [27]. These nanocarriers are often combined with other materials, such as polymers [47], hydrogels [48], and metal materials [49], to promote bone regrowth;

(2) PNMs can be used as an imaging contrast agent to trace the cells and monitor real-time tissue regeneration. Stem cell-based therapy is a promising approach in regenerative medicine [50]. However, the distribution and migration of stem cells after transplantation cannot be effectively monitored in vivo. To achieve this goal, an indirect or direct cell tracker is preferred [51]. Current approaches, such as indirect fluorescent reporter gene labeling, are challenging to obtain deep structure images in vivo with limited detection methods; furthermore, transgenic cells are difficult to use in clinical treatment due to the regulatory issues [52]. On the other hand, nanomaterials can be used to directly label cells and can be simultaneously detected with a variety of imaging methods including magnetic resonance (MRI) [53], computed tomography (CT) [54], and photoacoustic imaging (PI) [55,56]. Some products are already commercialized for this purpose as reviewed by Wang et al. [57]. PNMs have performed well in cell imaging studies. For instance, mesoporous silica shows excellent potential in stem cell tracking. The synthesized PEGylated gold/silica nanoparticle can simultaneously be detected by MRI, CT, and fluorescence imaging (FI) [58]. Jokerst, J.V., developed exosome-like silica nanoparticles, serving as a novel
ultrasound contrast agent for stem cell imaging [59]. Gadolinium\(^{3+}\)-doped mesoporous silica nanoparticles also served as a potential magnetic resonance tracer for monitoring the migration of stem cells in vivo [60]; (3) PNsMs have been used to fabricate or modify tissue-engineering scaffolds. The primary goal of tissue-engineered scaffolds is to develop an implant to replace the original bone tissue while supporting the regeneration process [61]. As mentioned above, natural bone has a micro-nanometer to a macroscopic hierarchical structure; thus, the tissue-engineered scaffolds must be designed in a three-dimensional structure with a highly porous feature, forming an interconnected pore network to mimic the structure of natural bone [62]. To achieve this goal, nanomaterials have been used to develop tissue-engineering scaffolds to improve the bone formation properties, such as cell growth, nutrient transport, new bone growth, and angiogenesis [52]. The physicochemical stability and mechanical properties of collagen hydrogel were improved by modification of aminated mesoporous bioactive glass in order to be better applied in tissue engineering stem cell culture [33]. Titanium dioxide nanotubes (TiO\(_2\) NPs) are a type of classic PNsMs with a diameter in the range of 30–100 nm, which have been widely used to construct and modify scaffolds to enhance cell attachment [63] and osseointegration [64,65]. N.K. summarized the potential applications of TNTs in implants [66]. Compared with the untreated titanium, TiO\(_2\) NTP-modified titanium enhanced the deposition of type I collagen when implanted into the porcine frontal skull. In addition, bone implants with TiO\(_2\) NT modification have good contact with bone and will not be damaged due to the fact of simple stress [67]. In a tibial bone defect model of rabbits, the TiO\(_2\) NT-modified implants induced a nine-fold increase in the bone binding rate compared to the non-modified implants [68]. In vitro and in vivo studies have shown that titanium dioxide nanotubes can increase the deposition of calcium and phosphorus and enhance the expression of osteogenesis genes such as alkaline phosphatase (ALP), osterix (Osx), and collagen-I (COL-I) [69]; (4) PNsMs have been regarded as an active substance to directly modulate cell behavior (cell adhesion and differentiation). Nanomaterials, themselves, are excellent enhancers of new bone formation. It is known that gold nanoparticle size and shape can influence the osteogenesis of mesenchymal stem cells [70]. In addition, porous materials, such as mesoporous bioactive glass nanoparticles [33–36,71], mesoporous hydroxyapatite [72], and mesoporous ceria (MCeO2) [37,38], have been found to directly promote osteoblast differentiation. For instance, cerium oxide nanoparticles-modified bioglass could enhance bone regeneration by activating the extracellular signal-regulated kinase (ERK) signaling pathway [38]. In another study, ceria nanocrystals, decorated with mesoporous silica nanoparticles, have been found to facilitate tissue regeneration via inducing reactive oxygen species-scavenging (therefore, avoiding tissue damage and inflammation), suggesting its potential in bone regeneration [73] Mesoporous Ce-doped bioactive glass nanoparticles could improve osteogenesis via Ce-induced anti-oxidation and anti-inflammation [74]. Similarly, nanoceria encapsulated within mesoporous silica nanoparticles (Ce@MSNs) have been found to facilitate bone regeneration in osteoporosis and that nanoceria could induce anti-oxidation and facilitate osteogenesis, ref. [75] suggesting that ceria could be considered a critical component in bone regenerative PNMs design. Moreover, ionic-doped PNMs can promote osteogenic differentiation and facilitate angiogenesis [76] and regulate immunity [77].

3. Autophagy Modulation and Bone Reconstruction

There are three main types of autophagy, namely, macroautophagy, microautophagy, and partner-mediated autophagy [78]. This review focuses on macroautophagy (hereinafter referred to as autophagy), a degradation process during which cellular wastes, such as damaged macromolecules and organelles, are accumulated at lysosomes by autophagy vesicles and removed [78]. Autophagy begins with cytoplasmic organelle isolation in bi-membranous vesicles called autophagosomes, which then fuse with lysosomes to form autophagosomes to degrade its contents by lysosomal hydrolases, such as damaged or-
Autophagy is one of the main mechanisms promoting cell survival, which is activated under stress conditions such as nutrient deprivation, oxidative stress, hypoxia, and infection [82]. For example, autophagy promotes the circulation of cellular components, thus providing energy for starving cells [83]. On the other hand, autophagy functions on clearing dysfunctional/damaged proteins and organelles [84]. For example, autophagy mediates the clearance of damaged mitochondria, also known as mitochondrial autophagy, inhibits the accumulation of reactive oxygen species (ROS), thereby protecting cells from oxidative stress and apoptosis [85]. These functions are thought to be essential in bone cell differentiation and immune cell polarization; thus, autophagy is believed to play a central role in bone regeneration (Figure 2).

Figure 2. Schematic diagram of autophagy-derived regulation on the differentiation/function of osteoclast/osteoblast and osteoimmunology. On the one hand, autophagy can facilitate the differentiation/function of both osteoclasts and osteoblasts; on the other hand, autophagy induces the phenotype switch from M1 (inflammatory phenotype, which facilitating osteoclastogenesis by producing IL-6 and iNOS) to M2 (tissue-regenerative phenotype, which facilitating osteogenesis by producing IL-10 and TGF-β) in the macrophage population, thereby generating an immune microenvironment favoring bone formation. Furthermore, autophagy induction on osteoblasts can reduce osteoblast-originated RANKL production, hence, reducing osteoclastogenesis by inhibiting the RANKL–RANK signaling pathway.

3.1. Autophagy in the Differentiation/Function of Osteoclasts and Osteoblasts

Bone is a metabolically active tissue composed of a network of various types of cells through multiple factors. To maintain physiological bone metabolism, different types of...
cells (e.g., stromal cells and immune cells) need to continuously interact with each other to ensure osteoblast differentiation, functional mineralization, and osteoclast phagocytosis. The process requires close coordination between cellular organelles and regulators and consumes a large amount of biological energy [86]. Bone metabolic homeostasis is maintained by the balance between osteoblast-derived bone formation and osteoclast-derived bone absorption [87]. Recent studies have confirmed that autophagy is involved in the mineralization process of osteoblasts and the maintenance of bone homeostasis [86]. Autophagy plays an essential role in the differentiation and function of osteoblasts and osteoclasts during bone regeneration. During the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation, autophagy-associated protein ATG 5/7/12 expression and LC3-II /LC3-I ratio increase with the degradation of p62 [88]. ATG5/7/4B and LC3 have also been reported to play a decisive role in regulating the production of osteoclast wrinkle boundary and lysosome secretion, thus determining the function of osteoclasts in vitro and in vivo [89].

On the other hand, autophagy participates in the differentiation and mineralization of osteoblasts. Autophagosomes act as cargos transporting intracellular mineral crystal-like structures to facilitate extracellular mineralization [90]. Inhibition of autophagy can result in impaired mineralization in vitro and reduced bone mass and volume in vivo, which is followed by oxidative stress and the production of RANKL in general [91]. These results suggest the fundamental role of autophagy in osteoblast differentiation and mineralization, which acts as a mineralization carrier to protect osteoblasts from increased oxidative stress and, in addition, to reduce the production of RANKL, thereby inhibiting osteoclastogenesis during bone formation [91].

3.2. Autophagy-Associated Immunomodulation in Bone Remodeling

Not only directly involved in the differentiation and function of osteoblast and osteoclast, autophagy also regulates the immune system which, in turn, regulates bone regeneration through modulating the immune microenvironment [13]. Among the immune cells, macrophages play an important role in the innate immune system. Macrophages are divided into un-activated M0 macrophages, proinflammatory M1 phenotype, and anti-inflammatory M2 phenotype. M1 macrophages are usually activated by microbial lipopolysaccharide (LPS) or Th1 cell-derived IFN, which are considered to promote osteoclastogenesis [92,93]. M2 macrophages, which are usually activated by TH2 cell-derived IL-4 or IL-13, are considered to be the subtypes that inhibit osteoclast differentiation and promote bone regeneration [92,93]. Especially in biomaterial-associated bone regeneration, macrophage phenotype switch from M1 to M2 is considered as an essential strategy in material design/development [94].

Autophagy plays an immunosuppressive role in macrophage inflammatory response. Atg5- or Atg16L1-deficiency on macrophages was found to induce the conversion of M2 macrophages into M1-like phenotypes with enhanced secretion of proinflammatory cytokines [95,96]. Mice with macrophage-specific ATG5-knockout showed induced systemic inflammation [97]. Primary bone marrow-derived macrophages (BMDMs) obtained from this mice type showed abnormal polarization with increased M1 polarization and decreased M2 polarization, indicating that inhibition or deficiency of autophagy can up-regulate inflammation in macrophages [97]. Further studies have found that autophagy facilitated the clearance of damaged mitochondria (mitochondrial autophagy, mitophagy). This process can effectively eliminate dysfunctional or damaged mitochondria, which can trigger inflammation and cause cell apoptosis or necrosis, thereby inhibiting inflammation and preventing unnecessary cell loss [98]. Autophagy plays a quality control role in inflammation regulation, and poor quality control can lead to inflammation and cell population death [98]. As previously mentioned, the inflammatory response of macrophages has been shown to induce osteoclast formation and bone loss. At the same time, the transformation of the proinflammatory M1 to anti-inflammatory M2 phenotype is thought to improve bone repair [99]. Therefore, this autophagy-mediated regulation of macrophage response
is beneficial to bone regeneration. Nanomaterial-derived autophagy induction has been shown to potentially introduce M2 polarization to improve bone regrowth [100], which further suggests that autophagy may be a potential immunomodulatory target in regenerative medicine, particularly for the treatment of bone loss diseases such as osteoporosis [101], arthritis [102], and periapical lesions [103].

4. PNMs Regulate Autophagy in Bone Regeneration

A great number of studies have demonstrated that certain types of PNMs can introduce autophagy activation [104]. PNM-induced autophagy could be a cellular mechanism either against or resulting from nano-toxicity [6]. In addition, both autophagy inhibition [105] and enhancement [106] have been reported as effective bone defect regeneration strategies. From these points, it could be speculated that autophagy acts like a “double-edged sword” in the treatment of bone regeneration. In this review, we summarize the recent progress of porous nanomaterials, including mesoporous silica-based nanoparticles (including mesoporous silica nanoparticles and mesoporous bioactive glass nanoparticles) [8,25,106–108], mesoporous hydroxyapatite nanoparticles [109–112], alumina nanoparticles [10,113], and metal titanium dioxide nanotubes [114,115] in promoting bone regeneration via autophagy modulation (Table 1). We especially emphasize the present mechanisms of autophagy regulation induced by PNMs and the role of autophagy regulation in determining cellular fate.

4.1. Mesoporous Silica-Based Nanomaterials (MSNs)

Mesoporous material is one of the most widely used porous materials with pore sizes between 2 and 50 nm [41]. The earliest mesoporous materials developed by researchers were disordered pore structures. In 1992, the scientific research team from the ExxonMobil corporation of the United States [116] first synthesized mesoporous silica with an ordered pore structure by using a surfactant. With the development of synthesis technology, mesoporous silica-based nanomaterials have rapidly become one of the most widely studied nanocarriers [117] due to the fact of their excellent properties including adjustable pores, size and spacing, easy functionalization, and good biocompatibility. Recent advances in biomedicine suggest that MSNs have been extensively investigated and applied in bone regeneration/tissue engineering. Vallet-regi, M., reported the research progress of mesoporous silica nanomaterials in treating complex bone diseases such as bone tumor, infection, and osteoporosis [118]. Chen, L., and Rosenholm, J.M., summarized the application of mesoporous silica nanomaterials in tissue engineering, including bone regeneration, vascular regeneration, and skin regeneration [119,120]. Eivazzadeh-keihan, R., further summarized the research progress of silica nanoparticles in bone tissue engineering [121]. Mesoporous bioactive glass nanomaterials, another kind of porous silica-based nanomaterials, are also widely used in bone regeneration research. Hae-won Kim proved that mesoporous bioactive glass nanoparticles can significantly improve the osteogenic capacity of implant materials, and that by using the mesoporous bioactive glass nanoparticles for surface modification of implants, the surface alkaline phosphate activity and expression of osteogenic genes (ALP, Col, OPN and OCN) [35] could be significantly improved. Bioactive glass modified with cerium oxide has been shown to clear ROS-promoting tissue regeneration and osteogenic differentiation [38,73]. With the extensive research of silica-based nanomaterials, more and more attention has been paid to the mechanism of its regulation on osteogenesis and its potential side effects.
| Item | Nanoparticles | Compound Carried/Combination Drugs | Target Cells | Autophagy Markers (Down/Up) | Autophagy Mechanism | Osteogenesis Marker (Down/up) | Biological Effect | Reference |
|------|---------------|-----------------------------------|--------------|----------------------------|--------------------|---------------------------|----------------|----------|
| 1    | Silica nanoparticles | Cobalt ferrite magnetic metal core | MC3T3-E1 cells | LC3II/LC3I ↑ P62 ↑ | ERK1/2-LC3 and P62 | ALP ↑ Alizarin red ↑ OSC ↑ | Autophagy and promoted osteoblast differentiation and mineralization | [25] |
| 2    | Mesoporous silica nanoparticles | No combination | RAW 264.7 cells | LC3II/LC3I ↑ | Not reported | Alizarin Red S ↑ | Autophagy and inhibited inflammation and promoted osteogenesis | [108] |
| 3    | Silica nanoparticles | Load BMP-2 plasmid | MC3T3-E1 | LC3II ↑ | Not reported | Alizarin red S ↑ | Stimulated autophagy, osteogenic differentiation, and bone regeneration | [107] |
| 4    | Silica-based nano-biomaterials | No combination | MSCs | LC3-ILC3 ↑ p-ERK/LC3 ↑ p-AKT/mAKT ↓ P-mTOR/mTOR | ERK1/2 and AKT/mTOR | ALP, mineralization level, COL, OPG, OCN, OPN, and RUNX2 ↑ | Enhanced the differentiation potential by enhancing autophagy | [8] |
| 5    | 45S5 bioglass | Sr doped | OVX-BMSCs | LC3A/LC3B ↑ | Not reported | OCN, OPN ↑ | Improved autophagy, promoted osteogenic differentiation of OVX-BMSCs and bone regeneration in osteoporotic bone defects | [106] |
| 6    | Nano-hydroxyapatite | Integrating nanoparticles within gelatin | MC3T3-E1 cells | LC3II/LC3I ↑ | mTOR | ALP, BMP2, BSP, COL, OCN, OPN, and Runx2 ↑ | Autophagy and modulated osteoblast differentiation | [112] |
| 7    | Hydroxyapatite NPs | No combination | Integrating nanoparticles within gelatin | rMSCs | LC3A/LC3B ↑ P62 ↑ | Not reported | OCN, OPN ↑ | Autophagy activation and promoted vascularized and bone regeneration | [111] |
| 8    | 45S5 bioglass | Sr doped | OVX-BMSCs | LC3A/LC3B ↑ | Not reported | OCN, OPN ↑ | Promoted autophagy and apoptosis to inhibit tumor growth while profoundly reducing bone destruction | [110] |
| 9    | Nano-hydroxyapatite | Integrating nanoparticles within gelatin | HMSCs | LC3B II ↑ Beclin-1 ↑ SQSTM1/P62 ↓ | AKT/mTOR and JNK | MMP-9 ↑ bone destruction ↓ | THA combined with metformin regulated autophagy, improved the activity of hPDLSCs, and promoted osteogenic differentiation | [109] |
| 10   | Polydopamine-templated hydroxyapatite (tHA) | Combined metformin | hPDLSCs | LC3B II ↑ Beclin-1 ↑ | AMPK/mTOR | OPN, Runx2, ALP activity, and Alizarin red ↑ | Activated autophagy and inhibited apoptosis | [113] |
| 11   | Nanosized alumina particle | Proteasome inhibitor, bortezomib (BTZ) | MG-63 cells | LC3 ↑ | Not reported | Apoptotic cell ↓ | Autophagy inhibited the expression of RANKL and inhibited osteolysis | [10] |
| 12   | Nanosized Al₂O₃ particle | No combination | Human fibroblasts | LC3II ↑ Beclin-1 ↑ BECN-1 | | | | Activated autophagy during osteogenic differentiation | [115] |
| 13   | Titanium oxide nanotubes | BMP2-stimulated macrophage-derived exosomes | hBMSCs | LC3II/LC3I ↑ ATG3 ↑ | | | | Activated autophagy and promoted osteogenesis by regulating bone immunity | [114] |
Many studies have shown that silicon dioxide induces autophagy modulation in a variety of cell lines [122]. Ha and co-authors found that silica nanoparticle-associated autophagy stimulation could be the cellular mechanisms of the enhanced osteogenic differentiation and mineralization [25]. They found that silica nanoparticles entered osteoblasts through vesicle-mediated endocytosis, which subsequently stimulated mitogen-activated protein kinase ERK1/2 (P44/P42) [25]. Their findings further revealed that silica nanoparticles stimulated autophagy, including the transition from LC3-MC-I to LC3-MC-II, an essential protein involved in autophagosome formation in an ERK1/2 signaling-dependent manner [25]. In addition, they used a variety of silica nanoparticles with a magnetic cobalt ferrite nucleus (NP1-MNP) to downregulate the relevant proteins and found that LC3 protein and p62, two critical proteins involved in autophagosome formation, bonded directly to silica nanoparticles [25]. Sun, H., et al. synthesized polyethyleneimine-modified porous silica nanoparticles (PPSNs), which can effectively carry plasmid bone morphogenetic protein 2 (PBMP-2), transferred it into MC3T3-E1 cells, and stimulated an autophagy pathway, leading to significant osteogenic differentiation and bone regeneration [107]. Cai, K.Y., et al. compared the effects of silica nanoparticles with different structures on mesenchymal stem cells [8]. It was found that solid silica nanoparticles (with the surface area of 35.938 m²/g) had a low capacity of protein absorption and could upregulate the expression of LC3-II through ERK1/2 and v-Akt murine thymoma viral oncogene/the mammalian target of rapamycin (AKT/mTOR) signaling pathways compared with mesoporous silica nanoparticles (with a pore size of 3.5 nm) and biodegradable mesoporous silica nanoparticles (with a pore size of 5.5 nm), thus leading to strong autophagy upregulation in MSCs [8]. Similarly, Sr-doping bioglass nanoparticles provide a promising strategy to promote osteogenic differentiation and bone regeneration in osteoporotic bone defect via early-stage induction of autophagy and later-stage activation of AKT/mTOR signaling pathway [106] in BMSCs.

Blood vessel regrowth is essential for bone regeneration. Sun, Z., et al. reported that negatively charged silicon dioxide nanoparticles resulted in dysregulation of cell homeostasis and angiogenesis through VEGFR2/PI3K/AKT/mTOR and VEGFR2/MAPK/ERK1/2/mTOR signaling pathways [123]. Moreover, there was crosstalk between the VEGFR2-mediated autophagy signaling and angiogenesis signaling pathways. Activation of autophagy by silica nanoparticles inhibited vascularization of endothelial cells [123]. Sun, Z.W., demonstrated that SiNPs triggered autophagy and apoptosis via ROS-mediated MAPK/Bcl-2 and PI3K/AKT/mTOR signaling in endothelial cells and, subsequently, disturbed the endothelial homeostasis and impaired endothelium [124]. Jeong-Ki Min demonstrated that SiO₂ nanoparticles could induce autophagy-directed cell necrosis via the PI3K/AKT/eNOS signaling axis in a size-dependent manner. The endothelial apoptosis and necrosis induced by 20 nm SiO₂ nanoparticles were more significant, while the SiO₂ nanoparticles at larger size had no significant effect [125]. These results may also be a mechanism of cardiovascular toxicity induced by MSNs [123–125].

Many studies have found that MSNs can be multicellular cytotoxic. For example, Wang et al. [126] reported that SiNPs increased LC3B expression in hepatocytes in a dose- and time-dependent manner, in accordance with the SiNP-induced cytotoxicity in hepatocytes. The study of Li, M., showed that the cytotoxicity of silica nanoparticles on macrophages was related to surface charge, and the cell survival rate increased with the surface modification of –COOH (negative charge), –NH₂ (positive charge), and polyethylene glycol (PEG, neutral) [127]. However, some researchers have discovered that MSNs have a positive effect on the cell viabilities of macrophages through inducing autophagy. Low concentrations of silica nanoparticles can protect macrophages from cytotoxicity by promoting an increase in autophagosomes or LC3-II levels [128]. In addition, our previous study reported that silica nanoparticles significantly inhibited the inflammatory response caused by macrophages, possibly due to the activation of autophagy through the Wnt5A/Ca²⁺ pathway [108]. Furthermore, such regulated immune microenvironment enhanced osteogenic differentiation of bone marrow MSCs, leading to increased mineralized nodules.
and alkaline phosphatase activity [108]. This suggests that the immune regulation mediated by mesoporous silica nanomaterials can be utilized in bone regeneration nanotherapy. Taken together, MSNs, a typical porous nanomaterial type used for bone regeneration, may function as an effective osteoimmunomodulator via autophagy regulation. MSN features, such as structure, dose-dependence, surface charge, and modification chemical groups, have been demonstrated to induce autophagy in BMSCs, an effect benefitting osteogenesis. Furthermore, MSNs, such as silica NPs, could regulate macrophage response via inducing autophagy, hence, generating an immune microenvironment beneficial for bone regeneration [108]. It is, therefore, speculated that MSNs should be designed with suitable chemical/physical properties, including the particle morphology, surface charge, chemical groups, water affinity, and drug loading/releasing efficiency, to induce favorable osteoimmunomodulation via inducing autophagy (Figure 3).

![Figure 3](image_url)  
**Figure 3.** Schematic diagram of MSNs targeting autophagy in bone regeneration. The physicochemical properties of porous silica-based nanomaterials, including morphology, surface properties (charge, hydrophilicity, chemical modification), drug loading, and release, should be the main factors modulating autophagy in bone regeneration.

### 4.2. Porous Nano-Hydroxyapatite (nHAP)

Hydroxyapatite (HAP, \(\text{Ca}_{10}(\text{OH})_2(\text{PO}_4)_6\)) has chemical properties similar to the inorganic component of the bone matrix. Due to the fact of its biomimetic structure (similar to natural bone tissue), researchers have been extensively investigating its translational potential, especially the synthetic hydroxyapatite as bone substitutes in the field of biomedical applications. Natural bone tissue is a complex organic/inorganic system composed of HAP and type I collagen fibers. HAP accounts for 70% of the bone, while collagen fiber accounts for 20%, and water accounts for approximately 10% of the whole. Because HAP is chemically similar to the inorganic components of the bone matrix, it has a strong affinity to host hard tissue. Due to the enhanced binding of HAP to host tissue, it has a significant advantage in clinical application over other bone substitutes (such as allograft or metal implants). Compared with micron-sized HAP, nano-HAP showed better biological properties as a bone defect implant and repair material, including induced cell activities, osteogenic properties, cell adhesions, and cell–matrix interactions [129,130], which are due to the fact of its peculiar nano-size properties (e.g., high surface area). Furthermore, porous HAP with high porosity and specific surface area has shown excellent biodegrad-
ability [131]. Molino, G sumeri [72] summarized the synthesis methods of mesoporous HAP and provided the mechanisms regarding the action of several surfactants (Cetyl trimethyl ammonium bromide (CTAB), F127, Triton X-100 as well as vitamin C) to control the size, shape, and porosity. Specifically, this method is based on using the surfactant as the template. The synthetic raw materials of HA are self-assembled cooperatively around the surfactant micelles as the template, and finally, calcination is performed to remove the templating agent and produce the pores in the particles [72]. As mentioned above, HAP has excellent osteogenic properties, and mesoporous nanometer HAP has a more outstanding performance in bone regeneration. Nga N.K. [132] using synthesized HAP nanoparticles to simulate biological apatite via a hydrothermal method using eggshells as precursors of biological calcium and with the assistance of CTAB. The HAP nanoparticles have a 2–6 nm pore size structure and have good biomineralization and protein adsorption capacity [132]. Frasnelli, M., [133] and Alshemary, A.Z., [134] synthesized strontium-doped mesoporous HAP nanoparticles via water deposition, which significantly promoted the proliferation and osteogenic differentiation of osteosarcoma cells in vitro, and strontium doping could significantly improve the expression of ALP.

Our previous work showed that HAP with different morphologies can activate autophagy of the rat MSCs to promote blood vessel and bone regeneration [111]. The scaffold constructed by nHAP with sphere morphology can also promote osteogenic differentiation by regulating autophagy, which has been further verified in vivo [111]. To investigate the mechanisms behind nHAP-promoted bone regeneration, Tian, W., at al. demonstrated that the internalized nHAP were located in typical autophagy vacuoles along with the increased LC3II/LC3I ratio, indicating that nHAP should be able to induce autophagy [112]. Further studies have found that HAP-induced autophagy is achieved through the mTOR signaling pathway in a concentration-dependent manner [112] which, in turn, enhances the osteogenic differentiation [112]. Another study verified that polydopamine-templated hydroxyapatite (tHA) resulted in induced cell cytotoxicity and reactive oxygen species (ROS) accumulation by inhibiting the expression of autophagy-related proteins beclin1 and LC3II in human periodontal ligament stem cells (hPDLSCs) [109]. The combination of tHA and metformin may prevent cytotoxicity in hPDLSCs exposed to tHA by reducing ROS via regulations on autophagy-related AMPK/mTOR signaling pathways, an effect that enhances the osteogenic differentiation of hPDLSCs [109]. On the other hand, hierarchically constructed bone-mimetic selenium-doped hydroxyapatite nanoparticles (B-SeHANs) promote the induction of autophagy and apoptosis via the ROS-mediated JNK-activation and AKT/mTOR-inhibition pathways in human MNNG/HOS osteosarcoma cells that suppressed bone tumor growth and reduced bone destruction [110]. From the above studies, it can be concluded that (Figure 4) nHAP can affect cell behaviors, such as cytotoxicity, differentiation, bone tumor growth, and bone destruction, by targeting autophagy in different cell types, which indicates that modulating autophagy may be a key mechanism for nHAP to promote bone regeneration.
Figure 4. Schematic diagram of hydroxyapatite NPs targeting autophagy in bone regeneration. The properties of hydroxyapatite nanomaterials, including morphology, size, dosage, and added elements, are considered the main autophagy regulators in osteogenesis. (Ga$^{3+}$: calcium ions; P$_3$O$_4^{3-}$: phosphate ion; Se$^{2-}$: selenium ions).

4.3. Titanium Dioxide Nanotubes (TiO$_2$ NTs) and Alumina Nanoparticles (Al$_2$O$_3$)

Metallic oxide nanoparticles are widely used in bone repair and reconstruction due to the fact of their unique and excellent properties. Metallic oxide nanoparticles are being used in bone-related investigations divided into three main categories: bioactive-molecule delivery, cell labeling, and surface modifications of implants and scaffolds. [135]. However, it is unclear about the mechanical and effect of metallic oxide nanomaterials in the skeletal system, especially the effects of these materials on autophagy caused are still largely unclear. This section mainly summarizes the current knowledge regarding porous metallic oxide nanomaterial (including TiO$_2$ NTs and Al$_2$O$_3$ nanoparticles) derived autophagy regulation in bone regeneration.

Recently, considerable attention has been devoted to the generation of titanium dioxide (TiO$_2$) through electrochemical anodization, a method that produces nanostructures to improve biocompatibility and cellular behavior on the surface of metal-based implants such as Ti, Ti-based alloys, tantalum (Ta), and zirconium (Zr) [136]. In particular, TiO$_2$ NTs with a diameter in the range of 30–100 nm have been found to facilitate cell attachment [63] and osseointegration [64,65]. Awad, N.K., summarized the potential applications of TiO$_2$ NTs in clinical implants [66]. Compared with untreated titanium, TiO$_2$ NT-modified titanium enhanced the deposition of type I collagen when implanted into a porcine frontal skull [67]. In addition, such implants showed good contacts with bone and would not be damaged by simple stress [67]. In a tibial implant model of rabbits, the TiO$_2$ NT-modified implants achieved a nine-fold increase in the bone binding rate compared to the non-modified implants [68]. In vitro and in vivo studies have shown that TiO$_2$ NTs can increase the deposition of calcium and phosphorus and enhance the expression of osteogenic factors such as alkaline phosphatase (ALP), osterix (Osx), and collagen-I (COL-I) [69]. Furthermore, functional modifications to the TiO$_2$ NT surface, such as combining with metal nanoparticles (gold nanoparticles or silver nanoparticles), grafting peptides, and delivering bone morphogenetic protein 2 (BMP2), can further improve the osteogenic properties of materials [137,138].
However, previous studies have found that the controversial effects of TiO$_2$ NPs on cell fate (regarding death and survival). Some studies discovered that TiO$_2$ NPs caused cell toxicology, while others reported that the proliferation and survival were enhanced in human fibroblast cells, epithelium, and osteoblasts cultured on TiO$_2$ NP-treated titanium surfaces [139]. Wang, H., has shown that autophagy regulates the Wnt/GSK3/β-catenin/cyclin D1 pathway in TiO$_2$-stimulated BMSCs to stimulate cell proliferation, autophagy-related protein (LC3II/I) expression in a TiO$_2$ NP concentration-dependent manner, which indicates that autophagy may be an essential mechanism for maintaining cell homeostasis under TiO$_2$-stimulated cell stress conditions [140]. Our studies used the exosomes from BMP2-stimulated macrophages to intrigue titanium oxide nanotubes to promote bone regeneration [115]. In this work, we found that autophagy could be activated during osteogenic differentiation by the functionalized titanium oxide nanotubes [115].

Porous metallic oxide nanomaterials have also been found to regulate immune response via autophagy modulation. Xiong, W., reported that silver nanoparticle-loaded TiO$_2$ nanotubes (Ag@TiO$_2$-NTs) could inhibit glucose transport protein type 1 (GLUT1) and promote autophagy levels in macrophages via suppressing phosphoinositide 3-kinase PI3K/AKT pathway, which induced the polarization toward M2-type, a beneficial effect for osteogenesis [114], as the conditioned medium of macrophage activated by Ag@TiO$_2$-NTs could significantly promote the expression of osteogenic genes ALP and Runx2 in MC3T3 pre-osteoblasts [114]. In addition, there have been studies regarding the alumina (Al$_2$O$_3$) nanoparticles with a pore size at the range of 1.3~4.1 nm [141,142]. Inflammation and osteolysis caused by wear debris often lead to implant or joint replacement failure, especially the activation of the NF-κB signaling pathway caused by wear debris has been shown to support the differentiation and maturation of osteoclasts. Zhang, Z., and their team reported that nanosized alumina particles prevented inflammation and osteolysis induced by titanium particles, a common wear debris, via autophagy and NF-κB (RANKL) signaling in MG-63 cells and mouse calvaria osteolysis model [113]. Moreover, Chen reported that Al$_2$O$_3$ particles promoted fibroblast autophagy in a time- and dose-dependent manner, while RANKL expression (an osteoclastogenesis factor) was negatively correlated with autophagy [10]. The result was further verified in a rat model of femoral head replacement [10]. They further found that LC3II expression was high, whereas RANKL expression was low in patients with the revised total hip arthroplasty with a ceramic interface [10]. This study suggests that autophagy induced by Al$_2$O$_3$ nanoparticles may have therapeutic potential for the prevention and treatment of osteolysis, which effectively inhibiting osteoclast formation and activation. In summary, TiO$_2$ and Al$_2$O$_3$ nanomaterials can modulate autophagy in MG-63 cells, human fibroblasts, hBMSCs, and macrophage RAW264.7 cells, and autophagy may serve as a key regulator in maintaining cell homeostasis promoting osteogenesis through immune regulation and inhibiting the formation and activation of osteoclasts (Figure 5).
Given the importance of autophagy in bone regeneration, it is necessary to include autophagy modulating function in the design and development of bone regenerative biomaterials. Although material properties, such as morphology, particle size, surface charge/chemical groups, and hydrophilicity have been found to affect cellular autophagy, the role of autophagy in bone regeneration and repair is not fully understood. It is essential to include autophagy in the design of bone regenerative materials to promote bone regeneration and repair.

PNMs have been widely used in regenerative medicine due to the fact of their excellent properties such as high porosity and high specific surface area. Autophagy, a process of self-digestion, may serve as an indispensable part of material-directed bone regeneration. Forous bioactive glass was first reported in 2014 to promote osteogenic differentiation by inducing autophagy. This work initialed the study of autophagy generated by bioactive nanomaterials to promote bone regeneration. Different from the previous opinion that autophagy can only promote cell death, this work considered that the induction of autophagy could be conducive to bone regeneration and repair, pointing out an important biological function of PNMs based on regulating autophagy. It provides a new idea for further research and development of bone regeneration materials. Recent studies have further revealed that PNMs can be used to regulate autophagy modulation in bone regeneration.

There are still many drawbacks in nanomaterial-derived autophagy regulation, mainly summarized in three aspects. First, at present, the research on autophagy induced by nanomaterials is still shallow and should be further explored. There is a lack of systematic research on the effects of physical and chemical properties of materials, such as properties, structure, morphology, and charge, on autophagy induction of cells, and more systematic and in-depth research is needed. Second, nanomaterials will form a layer of protein crown after entering cells or organisms that will affect the performance of materials in vivo. At present, the regulation of autophagy by the surface protein crown on materials is still lacking. Third, the current research is mostly cell- or animal-based and other preclinical research, and there is still a lack of adequate clinical experimental verifications.

Given the importance of autophagy in bone regeneration, it is necessary to include autophagy modulating function in the design and development of bone regenerative biomaterials. Although material properties, such as morphology, particle size, surface charge/chemical groups, and hydrophilicity have been found to affect cellular autophagy, the role of autophagy in bone regeneration and repair is not fully understood. It is essential to include autophagy in the design of bone regenerative materials to promote bone regeneration and repair.
level, it is yet to be explored what are the most ideal features for autophagy up- and downregulation to further refine the material design (Figure 6). In addition, advanced drug delivery system should be developed for specific cell-targeting (e.g., MSC-targeting, macrophage-targeting) controlled-release of autophagy regulators, such as small molecular chemicals (targeting PI3K/AKT, AMPK/mTOR, JNK, and ERK1/2 signaling pathways) and micro RNAs to facilitate different autophagy interventions according to certain cell types, thereby achieving advanced bone regeneration effects. With the considerable development space and good application prospect of nanotechnology in the field of regenerative medicine, PNM-induced autophagy will definitely write a new chapter in tissue engineering in the future.

Figure 6. Proposed strategies for future PMN design/development with autophagy-regulation function: one is to further investigate the effects of different material features on cellular autophagy, thereby facilitating the development of optimal autophagy-modulating materials; the other is to develop an advanced drug delivery system to facilitate specific cell-targeting autophagy regulation. Both of these two strategies aim to ensure the selective autophagy modulation on bone marrow stem cells (BMSCs) and macrophages to induce osteogenic differentiation (while reducing the receptor activator of nuclear factor-κB ligand (RANKL) expression and osteoclastogenesis) and macrophage polarization from M1 to M2, hence, generating a microenvironment favorable for bone regeneration.
Author Contributions: All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Q.Z.: involved in the concept and design of the article and wrote the manuscript. L.X.: involved in the conception, design, and revised the manuscript. Y.X.: involved in the conception and design of the article and reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Natural Science Foundation of China (NSFC, Grant No. 31771025 and 31971262) and the Health Science and Technology Project of Guangzhou City (Grant No. 20202A011026).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviation

PNMs porous nanomaterials
MSNs mesoporous silica nanoparticles
HAPs hydroxyapatite nanoparticles
MBGNs mesoporous bioactive glass
MCeO2 mesoporous ceria
MRI magnetic resonance
CT computed tomography
PI photoacoustic imaging
FI fluorescence imaging
TiO2 NTs Titanium dioxide nanotubes
ALP alkaline phosphatase
Osr osterix
COL-I collagen-I
ERK extracellular signal-regulated kinase
LC3 I microtubule-associated protein 1A/1B-light chain 3
LC3 II LC3-phosphatidylethanolamine conjugate
ROS reactive oxygen species
IL-6 interleukin 6
iNOS inducible nitric oxide synthase
IL-10 interleukin 10
TGF-β transforming growth factor-beta
RANKL the receptor activator of nuclear factor-κB ligand
LPS lipopolysaccharide
BMDMs bone marrow-derived macrophages
AKT v-Akt murine thymoma viral oncogene
mTOR the mammalian target of rapamycin
PEG polyethylene glycol
CTAB cetyl trimethyl ammonium bromide
hPDLSCs human periodontal ligament stem cells
B-SeHANs selenium-doped hydroxyapatite nanoparticles
Ga2+ calcium ion
P3O43− Phosphate ion
Se2− Selenium ion
Al2O3 alumina nanoparticle
BMP2 bone morphogenetic protein 2
GLUT1 glucose transport protein type 1
BMSCs bone marrow stem cells

References
1. Hadjidakis, D.J.; Androulakis, I.I. Bone remodeling. *Ann. N. Y. Acad. Sci.* 2006, 1092, 385–396. [CrossRef]
2. Li, Y.; Liu, C. Nanomaterial-based bone regeneration. *Nanoscale* 2017, 9, 4862–4874. [CrossRef] [PubMed]
28. Selvakumar, M.; Kumar, P.S.;Das, B.; Dhara, S.; Chattopadhyay, S. Structurally Tuned Antimicrobial Mesoporous Hydroxyapatite Nanorods by Cyclic Oligosaccharides Regulation to Release a Drug for Osteomyelitis. *Cryst. Growth Des.* 2016, 17, 433–445. [CrossRef]

29. Sistanipour, E.; Meshkini, A.; Oveisf, H. Catechin-conjugated mesoporous hydroxyapatite nanoparticle: A novel nano-antioxidant with enhanced osteogenic property. *Colloids Surf. B Biointerfaces* 2018, 169, 329–339. [CrossRef]

30. Qiu, Y.; Xu, X.; Guo, W.; Zhao, Y.; Su, J.; Chen, J. Mesoporous Hydroxyapatite Nanoparticles Mediate the Release and Bioactivity of BMP-2 for Enhanced Bone Regeneration. *ACS Biomater. Sci. Eng.* 2020, 6, 2323–2335. [CrossRef]

31. Walpole, A.R.; Briggs, E.P.; Karlsson, M.; Pälgård, E.; Wilshaw, P.R. Nano-porous Alumina Coatings for Improved Bone Implant Interfaces. *Mater. Werkst.* 2003, 34, 1064–1068. [CrossRef]

32. Briggs, E.P.; Walpole, A.R.; Wilshaw, P.R.; Karlsson, M.; Pälgård, E. Formation of highly adherent nano-porous aluminia on Ti-based substrates: A novel bone implant coating. *J. Mater. Sci. Mater. Med.* 2004, 15, 1021–1029. [CrossRef]

33. El-Fiqi, A.; Lee, J.H.; Lee, E.-J.; Kim, H.-W. Collagen hydrogels incorporated with surface-aminated mesoporous nanobioactive glass: Improvement of physicochemical stability and mechanical properties is effective for hard tissue engineering. *Acta Biomater.* 2013, 9, 9508–9521. [CrossRef]

34. Westhauser, F.; Wilkesmann, S.; Nawaz, Q.; Hohenbild, F.; Rehder, F.; Saur, M.; Fellenberg, J.; Moghaddam, A.; Ali, M.S.; Peukert, W.; et al. Effect of manganese, zinc, and copper on the biological and osteogenic properties of mesoporous bioactive glass nanoparticles. *J. Biomed. Mater. Res. Part A* 2021, 109, 1457–1467. [CrossRef]

35. Patel, K.D.; Buitrago, J.O.; Parthiban, S.P.; Lee, J.-H.; Singh, R.K.; Knowles, J.C.; Kim, H.-W. Combined Effects of Nanoroughness and Ions Produced by Electrodiposition of Mesoporous Bioglass Nanoparticle for Bone Regeneration. *ACS Appl. Bio Mater.* 2019, 2, 5190–5203. [CrossRef]

36. Kim, J.-J.; Singh, R.K.; Patel, K.D.; Kim, H.-W. Delivery of Small Genetic Molecules through Hollow Porous Nanoparticles Silences Target Gene and in Turn Stimulates Osteoblastic Differentiation. *Part. Part. Syst. Charact.* 2016, 33, 878–886. [CrossRef]

37. Xu, C.; Qu, X. Cerium oxide nanoparticle: A remarkably versatile rare earth nanomaterial for biological applications. *NPG Asia Mater.* 2014, 6, e90. [CrossRef]

38. Lu, B.; Zhu, D.-Y.; Yin, J.-H.; Xu, H.; Zhang, C.-Q.; Ke, Q.-F.; Gao, Y.-S.; Guo, Y.-P. Incorporation of cerium oxide in hollow mesoporous bioglass scaffolds for enhanced bone regeneration by activating the ERK signaling pathway. *Biofabrication* 2019, 11, 25012. [CrossRef] [PubMed]

39. Xiao, H.-T.; Wang, L.; Yu, B. Superparamagnetic iron oxide promotes osteogenic differentiation of rat adipose-derived stem cells. *Int. J. Clin. Exp. Med.* 2015, 8, 698–705.

40. Yun, W.S.; Aryal, S.; Ahn, Y.J.; Seo, Y.J.; Key, J. Engineered iron oxide nanoparticles to improve regenerative effects of mesenchymal stem cells. *Biomed. Eng. Lett.* 2020, 10, 259–273. [CrossRef] [PubMed]

41. Everett, D.H. Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry. Pure Appl. Chem. 1972, 31, 577–638. [CrossRef]

42. Zhou, X.; Weng, W.; Chen, B.; Feng, W.; Wang, W.; Nie, W.; Chen, L.; Mo, X.-M.; Su, J.; He, C. Mesoporous silica nanoparticles/gelatin porous composite scaffolds with localized and sustained release of vancomycin for treatment of infected bone defects. *J. Mater. Chem. B* 2018, 6, 740–752. [CrossRef]

43. Sun, X.; Zhang, J.; Wang, Z.; Liu, B.; Zhu, S.; Zhu, L.; Peng, B. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteolectast inhibition and bone loss prevention. *Theranostics* 2019, 9, 5183–5199. [CrossRef] [PubMed]

44. Cui, W.; Lü, Q.; Yang, L.; Wang, K.; Sun, T.; Ji, Y.; Liu, L.; Yu, W.; Qu, Y.; Wang, J.; et al. Sustained Delivery of BMP-2-Related Peptide from the True Bone Ceramics/Hollow Mesoporous Silica Nanoparticles Scaffold for Bone Tissue Regeneration. *ACS Biomater. Sci. Eng.* 2018, 4, 211–221. [CrossRef] [PubMed]

45. Zarif, F.; Tabassum, S.; Jamal, A.; Gul, U.; Gilani, M.A.; Shariif, F.; Zahid, S.; Asif, A.; Chaudhry, A.A.; Rehman, I.U. Surface-grafted remedial hydroxyapatite nanoparticles to avoid operational infections. *Mon. Chem. Chem. Mon.* 2019, 150, 605–615. [CrossRef]

46. Yang, Y.-H.; Liu, C.-H.; Liang, Y.-H.; Lin, F.; Wu, K.C.-W. Hollow mesoporous hydroxyapatite nanoparticles (hmHANPs) with enhanced drug loading and pH-responsive release properties for intracellular drug delivery. *J. Mater. Chem. B* 2013, 1, 2447–2450. [CrossRef]

47. Subhapradha, N.; Abudhahir, M.; Aithera, A.; Srinivasan, N.; Mookhi, A. Polymer coated mesoporous ceramic for drug delivery in bone tissue engineering. *Int. J. Biol. Macromol.* 2018, 110, 65–73. [CrossRef]

48. Lei, L.; Liu, Z.; Yuan, P.; Jin, R.; Wang, X.; Jiang, T.; Chen, X. Injectable colloidal hydrogel with mesoporous silica nanoparticles for osteolectast inhibition and bone loss prevention. *Theranostics* 2019, 9, 5183–5199. [CrossRef] [PubMed]

49. Liang, H.; Jin, C.; Ma, L.; Feng, X.; Deng, X.; Wu, S.; Liu, X.; Yang, C. Accelerated Bone Regeneration by Gold-Nanoparticle-Loaded Mesoporous Silica through Stimulating Immunomodulation. *ACS Appl. Mater. Interfaces* 2019, 11, 41758–41769. [CrossRef]

50. Mizuno, H.; Tobita, M.; Orbay, H.; Uysal, A.C.; Lu, F. Adipose-Derived Stem Cells as a Novel Tool for Future Regenerative Medicine. In *Stem Cells and Cancer Stem Cells*; Springer Science and Business Media LLC: Berlin/Heidelberg, Germany, 2014; Volume 12, pp. 165–174. [CrossRef] [PubMed]

51. Kiessling, F.; Mertens, M.E.; Grimm, J.; Lammers, T. Nanoparticles for Imaging: Top or Flop? *Radiology* 2014, 273, 10–28. [CrossRef]

52. Vieira, S.; Vial, S.; Reis, R.L.; Oliveira, J.M. Nanoparticles for bone tissue engineering. *Biotechnol. Prog.* 2017, 33, 590–611. [CrossRef] [PubMed]
53. Kempen, P.; Greasley, S.; Parker, K.A.; Campbell, J.C.; Chang, H.-Y.; Jones, J.; Sinclair, R.; Gambhir, S.S.; Jokerst, J.V. Theranostic Mesoporous Silica Nanoparticles Bio degrade after Pro-Survival Drug Delivery and Ultrasound/Magnetic Resonance Imaging of Stem Cells. *Theranostics* 2015, 5, 631–642. [CrossRef] [PubMed]

54. Wan, D.; Chen, D.; Li, K.; Qu, Y.; Sun, K.; Tao, K.; Dai, K.; Ai, S. Gold Nanoparticles as a Potential Cellular Probe for Tracking of Stem Cells in Bone Regeneration Using Dual-Energy Computed Tomography. *ACS Appl. Mater. Interfaces* 2016, 8, 32241–32249. [CrossRef] [PubMed]

55. Jokerst, J.V.; Khademi, C.; Gambhir, S.S. Intracellular Aggregation of Multimodal Silica Nanoparticles for Ultrasound-Guided Stem Cell Implantation. *Sci. Transl. Med.* 2013, 5, 177ra35. [CrossRef] [PubMed]

56. Jokerst, J.; Thangaraj, M.; Kempen, P.; Sinclair, R.; Gambhir, S.S. Photoacoustic Imaging of Mesenchymal Stem Cells in Living Mice via Silica-Coated Gold Nanorods. *ACS Nano* 2012, 6, 5920–5930. [CrossRef] [PubMed]

57. Wang, Y.; Xu, C.; Ow, H. Commercial Nanoparticles for Stem Cell Labeling and Tracking. *Theranostics* 2013, 3, 544–560. [CrossRef]

58. Van Schooneveld, M.M.; Cormode, D.P.; Koole, R.; Van Wijngaarden, J.T.; Calcagno, C.; Skajaa, T.; Hilhorst, J.; Hart, D.C.T.; Fayad, Z.A.; Mulder, W.J.M.; et al. A fluorescent, paramagnetic and PEGylated gold/silica nanoparticle for MRI, CT and fluorescence imaging. *Contrast Media Mol. Imaging* 2010, 5, 231–236. [CrossRef]

59. Chen, F.; Ma, M.; Wang, J.; Wang, F.; Chenn, S.-X.; Zhao, E.R.; Jhunjhunwala, A.; Darmadi, S.; Chen, H.; Jokerst, J.V. Exosome-like silica nanoparticles: A novel ultrasound contrast agent for stem cell imaging. *Nanoscale* 2017, 9, 402–411. [CrossRef]

60. Li, L.; Shen, Y.; Shao, Y.; He, H.; Tan, Y.; Tian, X.; Xie, F. Gadolinium3+-doped mesoporous silica nanoparticles as a potential magnetic resonance tracer for monitoring the migration of stem cells in vivo. *Int. J. Nanomed.* 2013, 8, 119–127. [CrossRef]

61. Qu, H.; Fu, H.; Han, Z.; Sun, Y. Biomaterials for bone tissue engineering scaffolds: A review. *RSC Adv.* 2019, 9, 26252–26262. [CrossRef]

62. Liu, C.; Xia, Z.; Czernuszka, J. Design and Development of Three-Dimensional Scaffolds for Tissue Engineering. *Chem. Eng. Res. Des.* 2007, 85, 1051–1064. [CrossRef]

63. Das, K.; Bose, S.; Bandypadhyay, A. TiO2 nanotubes on Ti: Influence of nanoscale morphology on bone cell-materials interaction. *J. Biomed. Mater. Res. Part A* 2008, 90, 225–237. [CrossRef]

64. Han, C.-M.; Kim, H.-E.; Koh, Y.-H. Creation of hierarchical micro/nano-porous TiO2 surface layer onto Ti implants for improved biocompatibility. *Surf. Coat. Technol.* 2014, 251, 226–231. [CrossRef]

65. Kim, M.-J.; Lim, H.-J.; Lee, B.G.; Kim, J.-H.; Choi, J.; Kang, H.-G. Establishment of Validation Methods to Test the Biocompatibility of Titanium Dioxide. *Bull. Korean Chem. Soc.* 2013, 34, 1857–1863. [CrossRef]

66. Awad, N.K.; Edwards, S.L.; Morsi, Y. A review of TiO2 NTs on Ti metal: Electrochemical synthesis, functionalization and potential use as bone implants. *Mater. Sci. Eng. C* 2017, 76, 1401–1412. [CrossRef]

67. von Wilmowsky, C.; Bauer, S.; Lutz, R.; Meisel, M.; Neukam, F.W.; Toyoshima, T.; Schmuki, P.; Nkenke, E.; Schlegel, K.A. In vivo evaluation of anodic TiO2 nanotubes: An experimental study in the pig. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2009, 89, 165–171. [CrossRef]

68. Bjursten, L.M.; Rasmussen, L.; Oh, S.; Smith, G.C.; Brummer, K.S.; Jin, S. Titanium dioxide nanotubes enhance bone bonding in vivo. *J. Biomed. Mater. Res. Part A* 2010, 92, 1218–1224.

69. Wang, N.; Li, H.; Liu, W.; Li, J.; Zhang, Z.; Liu, Y. Effects of TiO2 nanotubes with different diameters on gene expression and osseointegration of implants in minipigs. *Biomaterials* 2011, 32, 6900–6911. [CrossRef]

70. Li, J.; Li, J.; Zhang, J.; Wang, X.; Kawazoe, N.; Chen, G. Gold nanoparticle size and shape influence on osteogenesis of mesenchymal stem cells. *Nanoscale* 2016, 8, 7992–8007. [CrossRef]

71. Kong, C.H.; Steffi, C.; Shi, Z.; Wang, W. Development of mesoporous bioactive glass nanoparticles and its use in bone tissue engineering. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2018, 106, 2878–2887. [CrossRef]

72. Molino, G.; Palmieri, M.C.; Montalbano, G.; Fiorilli, S.L.; Vitale-Brovarone, C. Biomimetic and mesoporous nano-hydroxyapatite for bone tissue application: A short review. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 2019, 5, 22001. [CrossRef] [PubMed]

73. Wu, H.; Li, F.; Wang, S.; Lu, J.; Li, J.; Du, Y.; Sun, X.; Chen, X.; Gao, J.; Ling, D. Ceria nanocrystals decorated mesoporous silica nanoparticle based ROS-scavenging tissue adhesive for highly efficient regenerative wound healing. *Biomaterials* 2018, 151, 66–77. [CrossRef] [PubMed]

74. Zheng, K.; Torre, E.; Bari, A.; Taccardi, N.; Cassinelli, C.; Morra, M.; Fiorilli, S.; Vitale-Brovarone, C.; Iaviglia, G.; Boccaccini, A.R. Antioxidant mesoporous Ce-doped bioactive glass nanoparticles with anti-inflammatory and pro-osteogenic activities. *Mater. Today Bio* 2020, 5, 100041. [CrossRef] [PubMed]

75. Pini, A.; Baghbaderani, M.T.; Hernández, V.V.; Naruphontjirakul, P.; Li, S.; McFarlane, T.; Hachim, D.; Stevens, M.M.; Porter, A.E.; Jones, J.R. Nanoceria provides antioxidant and osteogenic properties to mesoporous silica nanoparticles for osteoradionecrosis treatment. *Acta Biomater.* 2020, 122, 365–376. [CrossRef] [PubMed]

76. Zhou, Y.; Sun, Z.; Chen, Z.;chang, J.; Wu, C.; Xiao, Y. Strategies to direct vascularisation using mesoporous bioactive glass-based biomaterials for bone regeneration. *Int. Mater. Rev.* 2017, 62, 392–414. [CrossRef]

77. Mountzias, P.M.; Mikos, A.G. Modulation of the inflammatory response for enhanced bone tissue regeneration. *Tissue Eng. Part B Rev.* 2008, 14, 179–186. [CrossRef]

78. Zhu, X.-R.; Du, J.-H. Autophagy: A potential target for the treatment of intraocular neovascularization. *Int. J. Ophthalmol.* 2018, 11, 695–698. [CrossRef]
79. Liu, L.; Xia, R.; Liu, X. MiR-125b-5p Promotes Autophagy in Systemic Lupus Erythematosus Cells by Up-Regulating the Expression of Genes Related to UV Resistance. *Acta Microbes*. 2020, 29, 2856–2865.
80. Kabeya, Y.; Mizushima, N.; Yamamoto, A.; Oshitani-Okamoto, S.; Ohsumi, Y.; Yoshimori, T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. *J. Cell Sci.* 2004, 117, 2805–2812. [CrossRef]
81. Chun, Y.; Kim, J. Autophagy: An Essential Degradation Program for Cellular Homeostasis and Life. *Cells* 2018, 7, 278. [CrossRef]
82. Avivar-Valderas, A.; Salas, E.; Bobrovnikova-Marjon, E.; Diehl, J.A.; Nagi, C.; Debnath, J.; Aguirre-Ghiso, J.A. PERK Integrates Autophagy and Oxidative Stress Responses to Promote Survival during Extracellular Matrix Detachment. *Mol. Cell. Biol.* 2011, 31, 3616–3629. [CrossRef]
83. Rambold, A.S.; Cohen, S.; Lippincott-Schwartz, J. Fatty Acid Trafficking in Starved Cells: Regulation by Lipid Droplet Lipolysis, Autophagy, and Mitochondrial Fusion Dynamics. *Dev. Cell* 2015, 32, 678–692. [CrossRef]
84. Mizushima, N.; Levine, B. Autophagy in mammalian development and differentiation. *Nat. Cell Biol.* 2010, 12, 823–830. [CrossRef] [PubMed]
85. Kim, I.; Rodriguez-Enriquez, S.; Lemasters, J.J. Selective degradation of mitochondria by mitophagy. *Arch. Biochem. Biophys.* 2007, 462, 245–253. [CrossRef] [PubMed]
86. Wang, S.; Deng, Z.; Ma, Y.; Jin, J.; Qi, F.; Li, S.; Liu, C.; Lyu, F.-J.; Zheng, Q. The Role of Autophagy and Mitophagy in Bone Metabolic Disorders. *Int. J. Biol. Sci.* 2020, 16, 2675–2691. [CrossRef]
87. Tanaka, Y.; Nakayamada, S.; Okada, Y. Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation. *Curr. Drug Targets-Inflamm. Allergy* 2005, 4, 325–328. [CrossRef] [PubMed]
88. Li, R.-F.; Chen, G.; Ren, J.-G.; Zhang, W.; Wu, Z.-X.; Liu, B.; Zhao, Y. The Adaptor Protein p62 Is Involved in RANKL-induced Autophagy and Osteoclastogenesis. *J. Histochem. Cytochem.* 2014, 62, 879–888. [CrossRef] [PubMed]
89. DeSelm, C.; Miller, B.; Zou, W.; Beatty, W.L.; van Meel, E.; Takahata, Y.; Klumperman, J.; Tooze, S.; Teitelbaum, S.L.; Virgin, H.W. Autophagy Proteins Regulate the Secretory Component of Osteoclastic Bone Resorption. *Dev. Cell* 2011, 21, 966–974. [CrossRef]
90. Li, Y.; Su, J.; Sun, W.; Cai, L.; Deng, Z. AMP-activated protein kinase stimulates osteoblast differentiation and mineralization through autophagy induction. *Int. J. Mol. Med.* 2018, 41, 2533–2544. [CrossRef]
91. Nollet, M.; Santucci-Darmanin, S.; Breuil, V.; Al-Sahlane, R.; Cros, C.; Topi, M.; Monier, D.; Samson, M.; Pagnotta, S.; Cailleteau, L.; et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. *Autophagy* 2014, 10, 1965–1977. [CrossRef]
92. Loi, F.; Cordova, L.A.; Zhang, R.; Pajarinen, J.; Lin, T.-H.; Goodman, S.B.; Yao, Z. The effects of immunomodulation by macrophage subsets on osteogenesis in vitro. *Stem Cell Res. Ther.* 2016, 7, 1–11. [CrossRef]
93. Zhang, Y.; Böse, T.; Unger, R.E.; Jansen, J.A.; Kirkpatrick, C.J.; Beucken, J.J.P.V.D. Macrophage type modulates osteogenic differentiation of adipose tissue MSCs. *Cell Tissue Res.* 2017, 369, 273–286. [CrossRef] [PubMed]
94. Chen, Z.; Klein, T.; Murray, R.R.; Crawford, R.; Chang, J.; Wu, C.; Xiao, Y. Osteoimmunomodulation for the development of advanced bone biomaterials. *Mater. Today* 2016, 19, 304–321. [CrossRef]
95. Zhao, W.; Li, Y.; Jia, L.; Pan, L.; Li, H.; Du, J. Atg5 deficiency-mediated mitophagy aggravates cardiac inflammation and injury in response to angiotensin II. *Free Radic. Biol. Med.* 2014, 69, 108–115. [CrossRef] [PubMed]
96. Symington, J.W.; Wang, C.; Twentyman, J.; Owusu-Boaitey, N.; Schwendener, R.A.; Nunez, G.; Schilling, J.D.; Mysorekar, I.U. ATG16L1 deficiency in macrophages drives clearance of uropathogenic E. coli in an IL-1β-dependent manner. *Mucosal Immunol.* 2015, 8, 1388–1399. [CrossRef] [PubMed]
97. Liu, K.; Zhao, E.; Ilyas, G.; Lalazar, G.; Lin, Y.; Haseeb, M.; Tanaka, K.E.; Czaja, M.J. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. *Autophagy* 2015, 11, 271–284. [CrossRef] [PubMed]
98. Green, D.R.; Galluzzi, L.; Kroemer, G. Mitochondria and the Autophagy-Immunoactivation-Cell Death Axis in Organismal Aging. *Science* 2011, 333, 1109–1112. [CrossRef] [PubMed]
99. Spiller, K.L.; Nassiri, S.; Witherel, C.E.; Anfang, R.R.; Ng, J.; Nakazawa, K.R.; Yu, T.; Unjukov-Novakovic, G. Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. *Biomaterials* 2015, 37, 194–207. [CrossRef]
100. Chen, Z.; Bachhuka, A.; Han, S.; Wei, F.; Lu, S.; Visalakshan, R.M.; Vasilev, K.; Xiao, Y. Tuning Chemistry and Topography of Nanoengineered Surfaces to Manipulate Response for Bone Regeneration Applications. *ACS Nano* 2017, 11, 4494–4506. [CrossRef] [PubMed]
101. Shen, G.; Ren, H.; Shang, Q.; Qiu, T.; Yu, X.; Zhang, Z.; Huang, J.; Zhao, W.; Zhang, Y.; Liang, D.; et al. Autophagy as a target for glucocorticoid-induced osteoporosis therapy. *Cell. Mol. Life Sci.* 2018, 75, 2683–2693. [CrossRef]
102. Vomero, M.; Barbatì, C.; Colasanti, T.; Perricone, C.; Novelli, L.; Ceccarelli, F.; Spinelli, F.R.; Di Franco, M.; Conti, F.; Valesini, G.; et al. Autophagy and Rheumatoid Arthritis: Current Knowledge and Future Perspectives. *Front. Immunol.* 2018, 9, 1577. [CrossRef] [PubMed]
103. Huang, H.Y.; Wang, W.-C.; Lin, P.Y.; Huang, C.P.; Chen, C.Y.; Chen, Y.K. The roles of autophagy and hypoxia in human inflammatory periapical lesions. *Int. Endod. J.* 2018, 51, e125–e145. [CrossRef] [PubMed]
104. Ning, F.; Yang, Z.; Xu, L.; Sun, Y. Targeted tumor therapy by autophagy of nanoparticles. *Futur. Oncol.* 2020, 16, 793–803. [CrossRef] [PubMed]
105. Cao, B.; Dai, X.; Wang, W. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca²⁺–calcineurin–NFATc1 pathway. *J. Cell. Physiol.* 2019, 234, 6831–6841. [CrossRef] [PubMed]
106. Zhang, X.; Cui, J.; Cheng, L.; Lin, K. Enhancement of osteoporotic bone regeneration by strontium-substituted 45S5 bioglass via time-dependent modulation of autophagy and the Akt/mTOR signaling pathway. J. Mater. Chem. B 2021, 9, 3489–3501. [CrossRef] [PubMed]

107. Xu, X.; Sun, M.; Wang, D.; Bu, W.; Wang, Z.; Shen, Y.; Zhang, K.; Zhou, D.; Yang, B.; Sun, H. Bone formation promoted by bone morphogenetic protein-2 plasmid-loaded porous silica nanoparticles with the involvement of autophagy. Nanoscale 2019, 11, 21953–21963. [CrossRef] [PubMed]

108. Chen, Z.; Han, S.; Shi, M.; Liu, G.; Chen, Z.; Chang, J.; Wu, C.; Xiao, Y. Immunomodulatory effects of mesoporous silica nanoparticles on osteogenesis: From nanoimmunotoxicity to nanoimmunotherapy. Appl. Mater. Today 2018, 10, 184–193. [CrossRef]

109. Yang, Z.; Gao, X.; Zhou, M.; Kuang, Y.; Xiang, M.; Li, J.; Song, J. Effect of metformin on human periodontal ligament stem cells cultured with polydopamine-templated hydroxyapatite. Eur. J. Oral Sci. 2019, 127, 210–221. [CrossRef]

110. Li, X.; Wang, Y.; Chen, Y.; Zhou, P.; Wei, K.; Wang, H.; Wang, J.; Fang, H.; Zhang, S. Hierarchically constructed selenium-doped bone-mimetic nanoparticles promote ROS-mediated autophagy and apoptosis for bone tumor inhibition. Biomaterials 2020, 257, 120253. [CrossRef]

111. Yang, G.; Liu, H.; Hu, X.; Chen, Z.; Friis, T.E.; Wang, J.; Xiao, Y.; Zhang, S. Bio-inspired hybrid nanoparticles promote vascularized bone regeneration in a morphology-dependent manner. Nanoscale 2017, 9, 5794–5805. [CrossRef]

112. Wang, R.; Hu, H.; Guo, J.; Wang, Q.; Cao, J.; Wang, H.; Li, G.; Mao, J.; Zou, X.; Chen, D.; et al. Nano-Hydroxyapatite Modulates Osteoblast Differentiation Through Autophagy Induction via mTOR Signaling Pathway. J. Biomed. Nanotechnol. 2019, 15, 405–415. [CrossRef]

113. Zhang, Z.; Fu, X.; Xu, L.; Hu, X.; Deng, F.; Yang, Z.; Jiang, L.; Fu, T.; Zhou, P.; Song, J. Nanosized alumina particle and proteasome inhibitor bortezomib prevented inflammation and osteolysis induced by titanium particle via autophagy and NF-κB. Signal. Sci. Rep. 2020, 10, 1–12. [CrossRef]

114. Chen, Y.; Guan, M.; Ren, R.; Gao, C.; Cheng, H.; Li, Y.; Gao, B.; Wei, Y.; Fu, J.; Sun, J.; et al. Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO2 Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy. Int. J. Nanomed. 2020, 15, 2011–2026. [CrossRef] [PubMed]

115. Wei, F.; Li, M.; Crawford, R.; Zhou, Y.; Xiao, Y. Exosome-integrated titanium oxide nanotubes for targeted bone regeneration. Acta Biomater. 2019, 86, 480–492. [CrossRef]

116. Kresge, C.T.; Leonowicz, M.E.; Roth, W.; Vartuli, J.C.; Beck, J.S. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nat. Cell Biol. 1992, 359, 710–712. [CrossRef]

117. Slowing, I.; Vivero-Escoto, J.L.; Wu, K.C.-W.; Lin, V.S.-Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 2008, 60, 1278–1288. [CrossRef] [PubMed]

118. Gisbert-Garzarán, M.; Manzano, M.; Vallet-Regí, M. Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis. Pharmaceutics 2020, 12, 83. [CrossRef] [PubMed]

119. Rosenholm, J.M.; Zhang, J.; Linden, M.; Sahlgren, C. Mesoporous silica nanoparticles in tissue engineering—A perspective. Nanomedicine 2016, 11, 391–402. [CrossRef]

120. Chen, L.; Zhou, X.; He, C. Mesoporous silica nanoparticles for tissue-engineering applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2019, 11, e1573. [CrossRef] [PubMed]

121. Eivazzadeh-Keihan, R.; Chenab, K.K.; Taheri-Ledari, R.; Mosafa, J.; Hashemi, S.M.; Mokhtarzadeh, A.; Maleki, A.; Hamblin, M.R. Recent advances in the application of mesoporous silica-based nanomaterials for bone tissue engineering. Mater. Sci. Eng. C 2020, 107, 110267. [CrossRef] [PubMed]

122. Guo, L.; He, N.; Zhao, Y.; Liu, T.; Deng, Y. Autophagy Modulated by Inorganic Nanomaterials. Theranostics 2020, 10, 3206–3222. [CrossRef] [PubMed]

123. Duan, J.; Yu, Y.; Yú, Y.; Li, Y.; Huang, P.; Zhou, X.; Peng, S.; Sun, Z. Silica nanoparticles enhance autophagic activity, disturb endothelial cell homeostasis and impair angiogenesis. Part. Fibre Toxicol. 2014, 11, 50. [CrossRef]

124. Guo, C.; Yang, M.; Jing, L.; Wang, J.; Yu, Y.; Li, Y.; Duan, J.; Zhou, X.; Li, Y. Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling. Int. J. Nanomed. 2016, 11, 5257–5267. [CrossRef] [PubMed]

125. Lee, K.; Lee, J.; Kwak, M.; Cho, Y.-I.; Hwang, B.; Cho, M.J.; Lee, N.G.; Park, J.; Lee, S.-H.; Park, J.-G.; et al. Two distinct cellular pathways leading to endothelial cell cytotoxicity by silica nanoparticle size. J. Nanobiotechnol. 2019, 17, 1–14. [CrossRef] [PubMed]

126. Wang, J.; Yu, Y.; Lu, K.; Yang, M.; Li, Y.; Zhou, X.; Sun, Z. Silica nanoparticles induce autophagy dysfunction via lysosomal impairment and inhibition of autophagosome degradation in hepatocytes. Int. J. Nanomed. 2017, 12, 809–825. [CrossRef]

127. Li, M.; Cheng, F.; Xue, C.; Wang, H.; Chen, C.; Du, Q.; Ge, D.; Sun, B. Surface modification of Stöber silica nanoparticles with controlled molarity densities determines their cytotoxicity profiles in macrophages. Langmuir 2019, 35, 14688–14695. [CrossRef]

128. Marquardt, C.; Fritsch-Decker, S.; Al-Rawi, M.; Diabate, S.; Weiss, C. Autophagy induced by silica nanoparticles protects RAW264.7 macrophages from cell death. Toxicology 2017, 379, 40–47. [CrossRef]

129. El-Fattah, H.A.; Helmy, Y.; El-Kholy, B.; Marie, M. In vivo animal histomorphometric study for evaluating biocompatibility and osteointegration of nano-hydroxyapatite as biomaterials in tissue engineering. J. Egypt. Natl. Cancer Inst. 2010, 22, 241–250.

130. Sadat-Shojai, M.; Khorasani, M.-T.; Dinpanah-Khoshdargi, E.; Jamshidi, A. Synthesis methods for nanosized hydroxyapatite with diverse structures. Acta Biomater. 2013, 9, 7591–7621. [CrossRef] [PubMed]
131. Hao, X.; Hu, X.; Zhang, C.; Chen, S.; Li, Z.; Yang, X.; Liu, H.; Jia, G.; Liu, D.; Ge, K.; et al. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxyapatite. ACS Nano 2015, 9, 9614–9625. [CrossRef]

132. Nga, N.K.; Chau, N.T.T.; Viet, P.H. Facile synthesis of hydroxyapatite nanoparticles mimicking biological apatite from eggshells for bone-tissue engineering. Colloids Surf. B Biointerfaces 2018, 172, 769–778. [CrossRef]

133. Frasnelli, M.; Cristofaro, F.; Sglavo, V.M.; Dirè, S.; Callone, E.; Ceccato, R.; Bruni, G.; Cornaglia, A.I.; Visai, L. Synthesis and characterization of strontium-substituted hydroxyapatite nanoparticles for bone regeneration. Mater. Sci. Eng. C 2017, 71, 653–662. [CrossRef]

134. Alshemary, A.Z.; Pazarçeviren, A.E.; Tezcaner, A.; Evis, Z. Mesoporous strontium doped nano sized sulphate hydroxyapatite as a novel biomaterial for bone tissue applications. RSC Adv. 2016, 6, 68058–68071. [CrossRef]

135. Walmsley, G.G.; McArdle, A.; Tevlin, R.; Momenti, A.; Atashroo, D.; Hu, M.S.; Feroze, A.H.; Wong, V.W.; Lorenz, P.H.; Longaker, M.T.; et al. Nanotechnology in bone tissue engineering. Nanomed. Nanotechnol. Biol. Med. 2015, 11, 1253–1263. [CrossRef]

136. Wang, L.; Jin, M.; Zheng, Y.-D.; Guan, Y.-P.; Lu, X.; Luo, J.-L. Nanotubular surface modification of metallic implants via electrochemical anodization technique. Int. J. Nanomed. 2014, 9, 4421–4435. [CrossRef] [PubMed]

137. Moon, K.-S.; Choi, E.-J.; Bae, J.-M.; Park, Y.-B.; Oh, S. Visible Light-Enhanced Antibacterial and Osteogenic Functionality of Au and Pt Nanoparticles Deposited on TiO2 Nanotubes. Materials 2020, 13, 3721. [CrossRef] [PubMed]

138. Gunputh, U.F.; Le, H.; Handy, R.D.; Tredwin, C. Anodised TiO2 nanotubes as a scaffold for antibacterial silver nanoparticles on titanium implants. Mater. Sci. Eng. C 2018, 91, 638–644. [CrossRef] [PubMed]

139. Bhardwaj, G.; Webster, T.J. Reduced bacterial growth and increased osteoblast proliferation on titanium with a nanophase TiO2 surface treatment. Int. J. Nanomed. 2017, 12, 363–369. [CrossRef] [PubMed]

140. Yu, S.; Wang, F.; Bi, Y.; Wang, P.; Zhang, R.; Bohatko-Naismith, J.; Zhang, X.; Wang, H. Autophagy regulates the Wnt/GSK3β/β-catenin/cyclin D1 pathway in mesenchymal stem cells (MSCs) exposed to titanium dioxide nanoparticles (TiO2NPs). Toxicol. Rep. 2020, 7, 1216–1222. [CrossRef]

141. Prashanth, P.; Raveendra, R.; Krishna, R.H.; Ananda, S.; Bhagya, N.; Nagabhushana, B.; Lingaraju, K.; Naika, H.R. Synthesis, characterizations, antibacterial and photoluminescence studies of solution combustion-derived α-Al2O3 nanoparticles. J. Asian Ceram. Soc. 2015, 3, 345–351. [CrossRef]

142. Ali, S.; Abbas, Y.; Zuhra, Z.; Butler, I.S. Synthesis of γ-alumina (Al2O3) nanoparticles and their potential for use as an adsorbent in the removal of methylene blue dye from industrial wastewater. Nanoscale Adv. 2019, 1, 213–218. [CrossRef]